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The goals of our research program arc: (1) to answer key questions regarding the biochemical 
mechanism responsible for the antihypertensive activity we have demonstrated for certain compounds 
of our design; (2) to bioassay the potential antihypertensive activity of other compounds we have 
already designed and synthesized based on the ideas of this proposal; and (3) to extend our efforts 
by continuing to design and evaluate other classes of compounds potentially capable of exhibiting 
antihypertensive activity through 0- ication of adrenergic neuronal activity. 
Substantial progress Iv 	 all of these areas. The following paragraphs 
summarize our progress dur :ear of the current project period. 
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Uptake snd Enz_yroatic Turnover in Cbrornaf fin Grapples.  The most likely mechanism by which 
these neurotransmitter analogs are causing an antihypertensive effect in spontaneously hypertensive 
rats (SHR) is thought to involve uptake into neuronal cells, followed by uptake into 
neurotransmitter storage vesicles. After uptake, by virtue of their ability to act either as D13/\I 
substrates or inhibitors, they effectively reduce the amount of norepinephrine (NE) stored in these 
vesicles and available for release and post-synaptic activation of adrenergic receptors. We have 
chosen initially to look at uptake into neurotransmitter storage vesicles. Since this is the critical 
step in the overall process, by performing these experiments first we can focus on the most 
promising compounds for subsequent testing in the more laborious whole-cell uptake and release 
experiments. Also, we are now utilizing a procedure which incorporates the recent elegant work 
from David Njus' laboratory where it has been demonstrated that "ghosts" derived from chromaffin 
granules are a much better model for these types of uptake and conversion experiments. 
Using this chrornaffin vesicle ghost protocol, we have now demonstrated uptake of the 
prototype selenium-containing analog, phenyl aminoethylselenide (PAESe), into these vesicular 
preparations. Furthermore, we have shown that the enzyme-dependent ascorbate recycling process 
we observed in free solution (see pp. 20-22 and pg. 31 of original proposal for rationale) does 
occur in these vesicle preps. We have demonstrated that uptake of PAESe into ghosts results in a 
ca. 50% reduction of vesicular ascorbate levels. In virtually identical experiments, we are now 
examining the effects of several of our sulfur-containing analogs on the vesicular uptake and 
conversion process. 
We chose to begin these vesicle studies by using the selenium-containing compound, PAESe, 
because of the sensitivity and ease with which we are able to measure changes in ascorbate levels 
within these ghosts using HPLC with electrochemical detection. For the work we propose to 
perform with the test compounds of the other classes, we must be able to acquire radiolabelled 
versions of the test compounds. To this end, we have set up a radiolabelling synthetic laboratory 
which yields ring-tritiated compounds of high specific activity. We have, to date, tritium-labelled 
one test compound, phenyl ethylenediamine (PEDA, one of our N-dealkylating analogs). During the 
coming year, we plan to extend this work to the other classes of compounds using essentially the 
same protocols. 
Dioassay of Antihypertensive Activity. 	We have developed a chronic dosing and measuring protocol 
for use with our olefinic and selenium-containing compounds since preliminary tests indicated that 
there was a 24-48 hour latency between dosing and the beginning of the antihypertensive effect. 
This protocol allows 'us to follow groups of SHR (control and drug-treated) over a two-week or 
more period, with dosing on a daily basis with measurement of blood pressure, heart rate, and 
body weight over the entire period. Using this new protocol, we have found that phenyl 
aminomethylethene (PANE, our prototypic olefin-containing analog) and phenyl aminocthylselenide 
(PAESe, a selenium-containing analog) both exhibit a marked, dose-dependent antihypertensive effect 
with as much as a 50% reduction in blood pressure and heart rate which begins ca. 48 hrs. after 
the first dose and extends for two weeks in both cases. 
As an important adjunct to these studies, we remove whole hearts at the end of the dosing 
period, and using HPLC with electrochemical detection, arc able to demonstrate a marked change in 
sympathetic nerve-ending catecholamines in the drug-treated animals. We have found a >50% 
reduction in norepinephrine and a >70% reduction in epinephrine from hearts of animals treated 
with PAESe which correlates with the effects on blood pressure and heart rate already noted. In 
the use of PANE, these effects are ca. -54% for NE and -80% for EPI. With both compounds we 
are also seeing a marked decrease in the weight of the hearts of those animals receiving the test 
compound. We think this may reflect a "blockage" of the developement of left ventricular 
hypertrophy which normally accompanies the etiology of hypertension, but have not conclusively 
proven this as yet. During the coming year we plan to further refine the bioassay using, for 
example, implanted osmotic pumps to continuously deliver compound doses in SHR, and plan to 
extend this bioassay to other compounds of different classes. 
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